We initiate coverage on Samsung Biologics with a narrow moat rating sourced from switching costs and a fair value estimate of KRW 688,700. Samsung Biologics is the largest South Korean contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results